BAFIERTAM Drug Patent Profile

When do Bafiertam patents expire, and when can generic versions of Bafiertam launch?

Bafiertam is a drug marketed by Banner Life Sciences and is included in one NDA. There are twenty-one patents protecting this drug.

The generic ingredient in BAFIERTAM is monomethyl fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the monomethyl fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Bafiertam

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 27, 2035. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BAFIERTAM

US Patents:	21
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	102
Clinical Trials:	3
Patent Applications:	3,609
Drug Prices:	Drug price information for BAFIERTAM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BAFIERTAM
What excipients (inactive ingredients) are in BAFIERTAM?	BAFIERTAM excipients list
DailyMed Link:	BAFIERTAM at DailyMed

See drug prices for BAFIERTAM

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BAFIERTAM

Constraining patent/regulatory exclusivity:

10,105,335

NDA:

210296

Dosage:

CAPSULE, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BAFIERTAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Banner Life Sciences LLC	Phase 1

See all BAFIERTAM clinical trials

US Patents and Regulatory Information for BAFIERTAM

BAFIERTAM is protected by twenty-one US patents.

This potential generic entry date is based on patent 10,105,335.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes	11,903,918
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes	10,918,617		Y
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296-001	Apr 28, 2020		RX	Yes	Yes	9,814,692

International Patents for BAFIERTAM

When does loss-of-exclusivity occur for BAFIERTAM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Denmark

European Patent Office

Israel

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BAFIERTAM around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015222880
Australia	2015328676
Australia	2016253548

BAFIERTAM (monomethyl fumarate) Market Dynamics and Financial Trajectory (2024–2029)

Last updated: July 30, 2026

BAFIERTAM (monomethyl fumarate, “MMF”) competes in U.S. multiple sclerosis (MS) with oral fumarate and higher-efficacy platform options. The drug’s financial trajectory is shaped by (1) steady demand from a long-lived oral MS segment, (2) pricing pressure from generics in adjacent fumarate classes and from payor preferencing toward multi-source options, and (3) patent and exclusivity timing that governs the near-term risk of generic erosion.

What follows is a market-and-finance profile that prioritizes: U.S. pricing and payor dynamics, competition, revenue exposure, and key inflection points by year.

---

How does BAFIERTAM make money in the U.S. MS market?

BAFIERTAM is marketed for relapsing forms of multiple sclerosis. MMF is positioned against dimethyl fumarate (DMF) and against newer oral and infusion therapies. Financial outcomes for BAFIERTAM track three variables common to MS orals:

1. Net price vs. list price
   MS oral net pricing typically reflects discounting, rebates, and PBM contracting. As more multi-source competitors appear in the oral MS ecosystem, net price usually compresses faster than wholesale acquisition cost.

2. Formulary access and prior authorization
   PBM steering for oral MS drugs often includes step edits (trial of a lower-cost oral) or “preferred fumarate” tiers. BAFIERTAM’s share is sensitive to these rules.

3. Persistence and tolerability
   MMF is a fumarate-class therapy with class-associated tolerability constraints (GI symptoms, flushing, and lab changes). Persistence affects LTV and the revenue curve even when dosing remains fixed.

BAFIERTAM demand drivers

• Patient substitution inside the same mechanism class: switching between MMF and DMF is common when tolerability or formulary status shifts.
• Escalation pressure from higher-efficacy agents: MS patients with active disease can move off fumarates to S1P modulators, anti-CD20, or other advanced options, shrinking long-term addressable demand.
• Reimbursement constraints: high rebate intensity is typical when the payer landscape becomes more competitive.

---

What MS competitors drive pricing and share shifts vs BAFIERTAM?

BAFIERTAM’s competitive set in the U.S. is broad, but revenue pressure tends to come from oral MS players because of formulary substitution.

Direct substitution: fumarates

• TECFIDERA (dimethyl fumarate)
  Often a first comparator in payer algorithms because it is also an oral fumarate. Net pricing and preferred-tier status for DMF are key to whether BAFIERTAM retains share.
• Generic or authorized multi-source fumarate products
  When multi-source fumarates gain preferential placement, BAFIERTAM’s growth ceiling lowers.

Indirect substitution: higher-efficacy platform therapies

• S1P modulators (oral)
  These can take share from fumarates when prescribers prioritize higher lesion control.
• Anti-CD20 and other infusible options
  These can pull forward conversion in active disease, affecting new starts into fumarate therapy.

Real-world market dynamics

In oral MS, share is often decided at the formulary level rather than through clinical differentiation. When payers move fumarates to preferred tiers that include multi-source options, the economics for single-brand MMF typically deteriorate.

---

When does BAFIERTAM lose exclusivity, and what is the generic launch risk?

The financial trajectory for BAFIERTAM is highly sensitive to generic entry timing. Generic launch risk is driven by:

• Orange Book exclusivity and patent cliffs
• Paragraph IV (PIV) challenge activity
• Settlement timelines
• Whether FDA has eligible listed patents for the specific dosage form/strength
• Manufacturing and formulation barriers that can delay approval

Key exposure mechanism: patent estate and PIV claims

For branded MS drugs, generic erosion often follows a pattern:

1. multi-source application readiness during late-stage prosecution,
2. PIV filings that force litigation and potential settlement,
3. launch upon patent expiry or a negotiated “carve-out” date.

Financial implication: revenue can show step-down behavior around the year a first generic product reaches pharmacy channels, with a second wave of erosion when additional ANDA approvals or authorized generics appear.

BAFIERTAM timeline impact framework (how to map to revenue)

• Pre-expiry: price support via exclusivity and limited contestability.
• PIV period: discounting increases as payers anticipate a lower-cost alternative.
• Launch year: revenue often declines faster than underlying patient attrition.
• Post-launch: share stabilizes at a lower level while net pricing collapses across the class.

---

What patents protect BAFIERTAM, and how many are typically tied to sales-critical claims?

A defensible patent estate for an oral MS therapy usually covers multiple claim categories:

• active ingredient and salts/esters,
• formulation and delivery characteristics,
• process and manufacturing,
• method of use (clinical indication),
• and sometimes polymorphs or stability-related improvements.

How the patent structure affects financial trajectory

• Formulation/process patents often delay “at-risk” generic manufacturing improvements.
• Method-of-use patents can delay indications-based substitution even if the active ingredient becomes generic.
• Expiration clustering determines whether generic pressure hits as a single cliff or as staggered erosion.

Practical investor take

The valuation of a mature oral MS franchise is mostly the present value of:

• remaining exclusivity years,
• expected net price during those years,
• and timing of generic competitive entries.

Without a detailed Orange Book + lawsuit map for BAFIERTAM, the only decision-grade statement is structural: BAFIERTAM economics depend on whether its patent estate has late-expiring formulation or use patents that survive beyond the earliest ingredient patent.

---

What is the Orange Book status of BAFIERTAM?

Orange Book status determines:

• listed patents tied to FDA approval,
• expiry dates,
• and exclusivity expiration (if any beyond patents).

Featured-snippet answer: Orange Book listings are the basis for determining whether future FDA generic approvals can rely on non-expiring claims or must wait out active patents.

Commercial implication: payers and generics price in Orange Book and PIV outcomes before public launch.

---

Has BAFIERTAM faced Paragraph IV challenges or patent litigation that affects market entry?

Generic market entry into MS orals is usually preconditioned on:

• PIV filings,
• litigation (often in federal district court),
• and settlements that set a defined launch date.

Financial translation of litigation

• If litigation stays active close to expiry, generic entry can be pushed back.
• If settlement results in early resolved licensing (authorizations or stipulated launch), revenue compression can start earlier than “hard” patent expiry.
• If litigation is resolved late in the year of expiry, pharmacies may delay switching until stocking clears.

Business impact: a stable revenue forecast requires knowing whether BAFIERTAM is in a “litigation-to-settlement” regime or an “uncontested expiry” regime.

---

How does BAFIERTAM compare with dimethyl fumarate (TECFIDERA) financially?

BAFIERTAM vs TECFIDERA economics are typically compared on three axes:

1. Formulary placement and PBM tiering
2. Net price trajectory under rebate competition
3. Persistence and tolerability-driven switching

General market pattern

• If TECFIDERA (or its multi-source versions) holds a preferred-tier position, BAFIERTAM’s growth slows.
• If payers prefer lower-cost fumarate options, BAFIERTAM faces share dilution even without direct clinical inferiority.

---

What financial risks exist for BAFIERTAM from generic substitution?

Generic substitution risk is not only about “whether generic exists.” It is also about whether generics:

• are placed on preferred tiers,
• have rebate structures that win formularies,
• are stocked broadly by PBM and wholesaler networks,
• and are treated as interchangeable in payer policies.

Key risk channels

• Price compression: net unit price drops once multiple suppliers compete.
• Share loss: oral MS switching rises as payers drive cost-lowering.
• Higher rebates to defend contracts: branded firms often pay more to preserve net share.
• Fewer new starts: formulary changes can stop onboarding new patients to BAFIERTAM.

---

What is the expected 2024–2029 revenue trajectory for BAFIERTAM?

Revenue trajectories for branded oral MS drugs typically follow a repeating curve:

• steady growth to mid-life driven by persistence and new starts,
• plateau as competitors gain share,
• decline around multi-source entry and exclusivity expiration.

Business-grade framing:

• If BAFIERTAM remains exclusive through the end of the period: the curve is likely “plateau then modest erosion” from higher-efficacy competition.
• If a generic launch occurs during the period: expect a step-down beginning at launch year, followed by sustained lower net revenue.

What to monitor to model the curve

• U.S. prescription trends (new starts, total prescriptions, persistence)
• PBM formulary changes (preferred tier migration)
• net price and rebate intensity changes
• litigation/PIV milestone updates

---

How do payer and reimbursement dynamics influence BAFIERTAM financials?

In oral MS, payers optimize total cost by steering patients to lower-cost agents within the same therapeutic class or within lower-tier coverage bands.

Mechanisms that move revenue

• Formulary tier changes: a change from non-preferred to preferred can drive measurable share gains.
• Step therapy and PA: strict step edits can slow adoption of MMF.
• Copay assistance pressure: as generics enter, payer advantage often shifts away from the brand, reducing copay program effectiveness.

---

Where does BAFIERTAM sit in the broader MS competitive landscape?

BAFIERTAM is part of a crowded oral MS ecosystem where clinical differentiation is less visible to payers than cost-to-benefit and access.

Competitive positioning

• Brand differentiator: historical clinician comfort with fumarates and real-world tolerability management.
• Economic differentiator: rebate and payer access strategy.
• Execution risk: loss of exclusivity or loss of preferred status can produce a rapid revenue drop.

---

Key Takeaways

• BAFIERTAM’s U.S. financial trajectory depends on formulary access, net price/rebate intensity, persistence, and generic entry timing.
• The market dynamics for MMF mirror those for oral MS: payer steering typically drives share more than incremental clinical nuance.
• Revenue modeling for BAFIERTAM should treat exclusivity expiry and Orange Book/litigation milestones as primary inflection points.
• Competitive pressure comes from fumarate class substitution (DMF) and broader oral MS platforms, with the biggest economic threat typically arriving from multi-source erosion.

---

FAQs

1. What share is BAFIERTAM likely to lose once a generic mmf product is launched in the U.S.?
2. How do PBMs usually decide between monomethyl fumarate and dimethyl fumarate?
3. What litigation milestones most affect the timing of ANDA launches for MS drugs?
4. Do method-of-use patents typically delay generic substitution for MS oral therapies?
5. How does copay assistance interact with payer preference when generics enter the fumarate class?

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. Drug Trials Snapshots (for approved products and labeling context). FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots